Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
AAPL$329.72-2.18(-0.66%)Apple Readies Launch of AI-Powered Health App7:42:21 PM ETAMGN$455.00-6.26(-1.36%)Amgen (AMGN) Reports Q3 Earnings: What Key Metrics Have to Say7:30:56 PM ETAAPL$329.72-2.18(-0.66%)Apple: 3 Key Takeaways for Long-Term Investors7:28:50 PM ETAMD$508.90+25.00(+5.17%)Here's why AMD's stock is rising — and sending a confident message about the AI trade7:17:00 PM ETAMD$508.90+25.00(+5.17%)AMD: Expensive For A Reason7:15:26 PM ETGOOG$277.20-0.80(-0.29%)Google responds to political backlash over removing search from schools that ban AI7:10:07 PM ETPLTR$172.83-2.57(-1.47%)Jim Cramer Says the Executioner Is “Axing Palantir and Apple.” What Investors Should Make of It7:09:17 PM ETABBV$285.06-0.94(-0.33%)AbbVie expands Oxford R&D facility as part of £120 million-plus investment7:08:52 PM ETTSLA$391.37-12.49(-3.09%)Tesla misled South Korean customers about automated-driving tech, consumer group alleges7:03:18 PM ETABBV$285.06-0.94(-0.33%)AbbVie expands Oxford R&D facility as part of £120 million-plus investment7:01:03 PM ETAMD$508.90+25.00(+5.17%)Advanced Micro (AMD) Reports Q3 Earnings: What Key Metrics Have to Say7:01:02 PM ETAMD$508.90+25.00(+5.17%)UPDATE 7-AMD forecast eases AI spending fears as data-center sales surge7:00:54 PM ETAMD$508.90+25.00(+5.17%)AMD: The Odds Are Getting Better, But The Bet Still Isn't Worth It (Upgrade)7:00:06 PM ETHSBC$84.63+0.14(+0.17%)HSBC Holdings: 3 Key Takeaways for Long-Term Investors7:00:02 PM ETAMD$508.90+25.00(+5.17%)Advanced Micro Devices (AMD) Q3 Earnings and Revenues Top Estimates6:51:30 PM ETDIS$114.07-0.11(-0.10%)Why Walt Disney (DIS) Outpaced the Stock Market Today6:46:07 PM ETHD$332.32-1.34(-0.40%)Home Depot (HD) Stock Falls Amid Market Uptick: What Investors Need to Know6:46:05 PM ETAMD$508.90+25.00(+5.17%)AMD Q3: Profits Are Booming, Cash Is Disappearing (Rating Downgrade)6:45:12 PM ETCRWD$243.44-1.24(-0.51%)CrowdStrike's new kill switch can stop rogue AI agents in their tracks, CEO says6:37:07 PM ETAMD$508.90+25.00(+5.17%)AMD Soars After Huge Guidance News6:30:29 PM ETAMGN$455.00-6.26(-1.36%)Amgen (AMGN) Tops Q3 Earnings and Revenue Estimates6:15:56 PM ETANET$186.80+16.89(+9.94%)Arista Networks (ANET) Q3 Earnings and Revenues Beat Estimates6:15:53 PM ETAMD$508.90+25.00(+5.17%)AMD: Don't Chase The Record Quarter6:10:20 PM ETAMD$508.90+25.00(+5.17%)BRIEF-AMD CEO - Now Expect Revenue to Grow More Than 80% in 20276:02:02 PM ET

CORT · NASDAQ

Corcept Therapeutics Incorporated

$79.50 -1.00 (-1.24%)

Company overview

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets, a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome, as well as nab-paclitaxel in combination with relacorilant, which has completed a Phase II clinical trial for the treatment of patients with advanced ovarian tumors and for cortisol excess.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$8.6B
Employees
500
Headquarters
Menlo Park, CA
Website
corcept.com
CEO
Joseph K. Belanoff
Listed
April 14, 2004
P/E
176.67
Dividend yield
0.00%

Company financials

Revenue
$769M
Gross profit
$756M
Operating income
-$8.2M
EBITDA
-$6.8M
Net income
$47.9M
EPS
$0.45
Total assets
$815M
Total debt
$9.6M
Gross margin
98.25%
Net margin
6.23%
Earnings yield
0.57%

Price chart

42.5064.2886.06107.83129.61
CORT 1D NASDAQ O80.93H82.23L79.40C80.46-0.66 (-0.81%)Vol1.59M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
CORTCorcept Therapeutics Incorporated Stock news Corcept Therapeutics Q3 Earnings Call Highlights MarketBeat
CORTCorcept Therapeutics Incorporated Stock news Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates Zacks Investment Research
CORTCorcept Therapeutics Incorporated Stock news Corcept Therapeutics Q3 revenue beats estimates on strong Lifyorli uptake Reuters
CORTCorcept Therapeutics Incorporated Press release Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update Business Wire
CORTCorcept Therapeutics Incorporated Press release Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call Business Wire
CORTCorcept Therapeutics Incorporated Press release Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer Business Wire
CORTCorcept Therapeutics Incorporated Press release 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Business Wire
CORTCorcept Therapeutics Incorporated Stock news Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym? Zacks Investment Research
CORTCorcept Therapeutics Incorporated Stock news Corcept Therapeutics (NASDAQ:CORT) Director Sells $1,148,100.00 in Stock Defense World
CORTCorcept Therapeutics Incorporated Stock news Corcept Therapeutics Incorporated $CORT Stock Holdings Cut by First Citizens Bank & Trust Co. Defense World
CORTCorcept Therapeutics Incorporated Stock news 3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge Zacks Investment Research
CORTCorcept Therapeutics Incorporated Stock news Are Medical Stocks Lagging Aspen Pharmacare (APNHY) This Year? Zacks Investment Research
CORTCorcept Therapeutics Incorporated Stock news Analyzing Xeris Biopharma (NASDAQ:XERS) and Corcept Therapeutics (NASDAQ:CORT) Defense World
CORTCorcept Therapeutics Incorporated Stock news 4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike Zacks Investment Research
CORTCorcept Therapeutics Incorporated Press release Corcept Announces Planned Leadership Transition Business Wire
CORTCorcept Therapeutics Incorporated Stock news CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer Zacks Investment Research
CORTCorcept Therapeutics Incorporated Stock news Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Insider Sells $29,842.72 in Stock Defense World
CORTCorcept Therapeutics Incorporated Press release Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant) Business Wire
CORTCorcept Therapeutics Incorporated Stock news Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026? Zacks Investment Research
CORTCorcept Therapeutics Incorporated Stock news Corcept Grows to Mid-Cap on Institutional Support FXEmpire
See more
FAQ

Questions about Corcept Therapeutics Incorporated

What does Corcept Therapeutics Incorporated do?
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets, a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome, as well as nab-paclitaxel in combination with relacorilant, which has completed a Phase II clinical trial for the treatment of patients with advanced ovarian tumors and for cortisol excess.
What is CORT's market cap?
Corcept Therapeutics Incorporated (CORT) is a listed stock with a live quote. The latest market cap on this page is $8.6B.
Where is Corcept Therapeutics Incorporated headquartered?
Corcept Therapeutics Incorporated is headquartered in Menlo Park, CA.
How do I get CORT news from the API?
Call GET /v1/news?tickers=CORT. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does CORT news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for CORT, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the CORT price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs